Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.

Original languageEnglish (US)
Pages (from-to)1169-1173
Number of pages5
JournalJournal of diabetes science and technology
Volume10
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Medical problems
Glucose
Monitoring
Blood Glucose Self-Monitoring
Therapeutics
Blood Glucose
Artificial Pancreas
Blood
Type 1 Diabetes Mellitus
Patient Care
Health
Technology
Delivery of Health Care
Feedback

Keywords

  • Artificial pancreas
  • Continuous glucose monitoring
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Cite this

Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions. / Castle, Jessica; Jacobs, Peter.

In: Journal of diabetes science and technology, Vol. 10, No. 5, 2016, p. 1169-1173.

Research output: Contribution to journalReview article

@article{53bc692937a04d618d11692c08091f47,
title = "Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions",
abstract = "While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.",
keywords = "Artificial pancreas, Continuous glucose monitoring, Type 1 diabetes",
author = "Jessica Castle and Peter Jacobs",
year = "2016",
doi = "10.1177/1932296816631569",
language = "English (US)",
volume = "10",
pages = "1169--1173",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "5",

}

TY - JOUR

T1 - Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions

AU - Castle, Jessica

AU - Jacobs, Peter

PY - 2016

Y1 - 2016

N2 - While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.

AB - While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.

KW - Artificial pancreas

KW - Continuous glucose monitoring

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85012980073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012980073&partnerID=8YFLogxK

U2 - 10.1177/1932296816631569

DO - 10.1177/1932296816631569

M3 - Review article

C2 - 26880390

AN - SCOPUS:85012980073

VL - 10

SP - 1169

EP - 1173

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 5

ER -